Robert Plenge
@rplenge
Followers
6K
Following
3K
Media
661
Statuses
5K
EVP, Chief Research Officer at BMS; physician-scientist; human genetics; father of 3 girls
Boston, MA (USA)
Joined November 2012
My #SXSW2026 proposal is open for voting! I’ll explore how lessons from poker can help scientists drive breakthroughs for patients. To vote, go to https://t.co/oGya4Abb7Z search “All In: Drug Discovery, Poker, and the Power of Uncertainty,” and click the 💓 icon. #BMS_employee
1
0
6
Honored, humbled and excited to become the inaugural Chair of @MassGenBrigham Department of Medicine @MGHMedicine @BrighamWomens. Grateful to continue working with Bruce Levy and Colleen Curry in a unified Department as we navigate tumultuous waters ahead. AMCs have a future!
18
21
233
How is biopharma R&D like Texas hold ‘em poker? My new PlengeGen blog discusses a critical inflection point in early clinical drug development and the investment required to deliver the necessary proof-of-concept data. https://t.co/Q044kOAg7l
plengegen.com
In a previous blog post, I argued that pharmaceutical Research and Development (R&D) is more like poker than chess given the probabilistic nature of developing new medicines. In this blog, I build...
3
3
19
Congratulations, Edith Heard! The EMBL Director General has been awarded the CNRS Gold Medal 2024 for her outstanding contributions to French research and her work on epigenetics and X-chromosome inactivation. https://t.co/frx7jzGY7p
0
9
93
A wrote a blog "advice to my younger self". I then uploaded the blog into Illuminate to create an AI podcast. Even if you don't like the advice, listen to the podcast...it is pretty amazing what AI can do! AI podcast: https://t.co/NzjdYoNftb Blog:
3
2
19
@jflier Really fascinating article on GLP1. Q1: given knowledge in 1997, do you think PFE approached decision in wrong way? Q2: what about calbio - arguably they achieved great exit in relatively short time - seems far less likely for GLP1. Q3: Your POV on decision-making here?
2
1
2
I've noticed that biotech cos built around a computational discovery platform have a different philosophy on company building and how to use software to gain sustainable advantage vs. 'traditional' biotech or pharma. I reflect on this in a new blog post:
atelfo.github.io
Reflections on the differing philosophies of company building between biotechs with and without a core computational discovery platform
7
36
232
I’m thrilled to share that our work from the @VAResearch is finally out in @ScienceMagazine ! We dive deep into the genetic architecture of 2,068 traits using data from the VA Million Veteran Program, comprising 635,969 Veteran. https://t.co/UnPZRk0QwE
9
53
136
Please join us in welcoming Chris Schade, Lynne Parshall, @rplenge, and @NancySimonian, who join @afzelius_lovisa and Michelle Werner on Alltrna’s Board of Directors. Their expertise will help guide us as we advance our first #tRNA medicines to the clinic for #StopCodonDisease
0
1
2
Our Head of Research, @rplenge, explains the components of our strategic research framework and how our differentiated platforms set us apart. See why he’s excited by the scientific innovation and collaborations underway enabling us to transform patients' lives through science.
0
1
4
New on https://t.co/k8qyHslckS: How our sequential immunotherapy research strategy @bmsnews strives to provide durable remissions and even functional cures for patients with #autoimmune diseases.
plengegen.com
Disclaimer: I am a full-time employee of Bristol Myers Squibb. When I practiced clinical rheumatology, I would often see patients with autoimmune conditions like systemic lupus erythematosus (SLE),...
1
2
26
Looking forward to exploring a successful transition from academia to industry with @rplenge this afternoon over food and drink @harvardmed for the Biomedical Informatics Entrepreneurs Salon #BIES
Tuesday 5/28/24: Biomedical Informatics Entrepreneurs Salon #BIES hosted by @zakkohane w/ @HarvardTechXfer 🍕🥤🍪 4:30pm In-person food/drink/network at HMS 🗣️🧠💡5:00–6:00pm (Zoom option) Robert Plenge, @rplenge @bmsnews Bristol Myers Squibb Register: https://t.co/kP1pzGVfGW
1
5
15
Tuesday 5/28/24: Biomedical Informatics Entrepreneurs Salon #BIES hosted by @zakkohane w/ @HarvardTechXfer 🍕🥤🍪 4:30pm In-person food/drink/network at HMS 🗣️🧠💡5:00–6:00pm (Zoom option) Robert Plenge, @rplenge @bmsnews Bristol Myers Squibb Register: https://t.co/kP1pzGVfGW
0
7
11
New pre-print from the @PGCgenetics #Depression Group: Multi-ancestry GWAS of depression with 685,000 cases identifies 697 independent associations, implicating known & novel drug targets. 🔗 https://t.co/eAh41d9XfA 1/n
2
51
95
Another fascinating interview - with @rplenge, head of research at @bmsnews : Causal biology is the North Star of R&D. (Open access). https://t.co/4W43IKiHcB via @YouTube
0
5
9
And link to the interview on YouTube is here: https://t.co/pRosbCjjfY
0
0
1
I had a great conversation with @FishburnSimone on The @BioCentury Show, covering the core components of our research framework at BMS, including causal human biology, matching modality to mechanism, and path to clinical proof of concept.
biocentury.com
Within the framework of target, modality and path to clinic, causal biology is the axis along which Robert Plenge is building and prosecuting research at B...
1
3
12
I had the pleasure of speaking with @NatRevDrugDisc about one of the topics I’m most passionate about: the potential of sequential immunotherapy to treat autoimmune diseases. We also discussed genetics and its role in causal human biology.
nature.com
Nature Reviews Drug Discovery - Robert Plenge, head of Research at Bristol Myers Squibb, discusses his vision of sequential immunotherapy for autoimmune diseases — including multiple sclerosis.
1
8
47
Excited to share the first publication from Oda lab in @NatImmunol !! We describe human SHARPIN deficiency as a novel member of 'inborn errors of cell death'. A great collaboration with Dan Kastner, @Bee191961, and @NajouaLalaoui. https://t.co/XKqWfzvpRY
6
14
74